Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $163.64 on Friday. The business has a fifty day moving average of $181.27 and a 200 day moving average of $185.06. Krystal Biotech, Inc. has a 1 year low of $107.50 and a 1 year high of $219.34. The firm has a market capitalization of $4.71 billion, a price-to-earnings ratio of 92.45 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.67) EPS. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. grew its position in Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech in the third quarter worth about $40,000. Teachers Retirement System of The State of Kentucky grew its holdings in Krystal Biotech by 198.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company’s stock worth $1,640,000 after acquiring an additional 5,989 shares during the period. Geode Capital Management LLC raised its position in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after acquiring an additional 11,411 shares in the last quarter. Finally, Main Management ETF Advisors LLC acquired a new position in Krystal Biotech in the third quarter valued at approximately $706,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Chardan Capital reiterated a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a report on Thursday. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Citigroup lifted their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and an average target price of $206.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).